miR‐1343‐3p通过直接向多发性骨髓瘤细胞中的ATG7来抑制自
Yanrong Guo1, Xiaoxiao Ding1, Changling Dai1
1Department of Hematology, Taizhou Central Hospital (Taizhou University Affiliated Hospital), Taizhou University, Taizhou, Zhejiang 318008, P.R. China.
Biomedical reports
|October 18, 2024
概括
在多发性骨髓瘤细胞中,MicroRNA-1343-3p向ATG7,这是一种参与自的基因. 这种微RNA可能为治疗这种血液性恶性瘤提供了一个新的治疗策略.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 多发性骨髓瘤 (MM) 是一种流行的血液性恶性瘤,尽管有先进的治疗方法,预后不佳.
- MM的潜在病理机制在很大程度上是未知的.
- 确定新的治疗点对于改善患者的治疗结果至关重要.
研究的目的:
- 研究微RNA (miR)-1343-3p在多发性骨髓瘤中与自相关的7 (ATG7) 的调节中的作用.
- 探索miR-1343-3p作为MM治疗点的潜力.
主要方法:
- 使用TargetScan进行生物信息预测,以识别ATG7作为miR-1343-3p的目标.
- 双露西法酶记者测定证实了miR-1343-3p和ATG7 3'UTR之间的相互作用.
- 反转录定量PCR (RT-qPCR) 和西部斑点分析以评估基因和蛋白质表达水平.
- 细胞活力测试评估miR-1343-3p对MM细胞存活率的影响.
主要成果:
- miR-1343-3p直接针对ATG7.7的3'未翻译区域 (3'UTR).
- 与miR-1343-3p的传染模仿了MM细胞系中ATG7mRNA和蛋白质水平的降低.
- 抑制miR-1343-3p导致ATG7表达的增加.
- miR-1343-3p模仿转染抑制了U266和RPMI-8226MM细胞的生存.
- 证明miR-1343-3p可以调节MM细胞中的ATG7和自.
结论:
- miR-1343-3p直接向ATG7,影响多发性骨髓瘤细胞的自.
- 这些发现表明miR-1343-3p在MM发展中起着重要作用.
- miR-1343-3p代表了多发性骨髓瘤治疗的潜在新型治疗点.
更多相关视频
09:10siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells
Published on: October 28, 2019
7.2K
11:39Assessing Autophagic Flux by Measuring LC3, p62, and LAMP1 Co-localization Using Multispectral Imaging Flow Cytometry
Published on: July 21, 2017
31.2K
相关概念视频
Autophagy
4.2K
Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
MicroRNAs
21.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.2K
